Latest news with #Hims
CNBC
2 days ago
- Business
- CNBC
Hims to cut 4% of workforce amid ban on weight-loss drug copies
NEW YORK, May 30 (Reuters) - Telehealth platform Hims & Hers (HIMS.N), opens new tab will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug Administration ban on compounded copies of Wegovy, made by Novo Nordisk ( opens new tab, took effect on May 22. Hims shares have since dropped 14%. The company confirmed the job cuts in a statement on Friday. On Saturday, it said that the reductions were not related to the compounding ban. Hims did not provide details about the roles that were cut, but said they were implemented across teams. "These changes are focused on sharpening how we execute, without affecting our priorities or the specialties we're committed to," a company spokesperson said regarding the layoffs. Hims still plans to hire for roles related to its long-term growth strategy. The company recently announced an agreement with Novo to help patients access brand-name Wegovy. It plans to enter the market for low testosterone and menopause treatments and is looking at offerings to improve longevity and sleep. Bloomberg News reported the job cuts earlier on Friday. In 2022, the FDA declared a shortage of Wegovy, which has been shown to help patients lose around 15% of their body weight. That declaration allowed compounding pharmacies to produce the drug to meet demand. Hims began offering copies of Wegovy in 2024, often at far lower prices than the brand-name version. That boosted subscriptions to the Hims telehealth platform, with revenue up 111% on a yearly basis during the first quarter of 2025. Wegovy copies and similar GLP-1 weight-loss drugs accounted for $200 million of the company's $1.5 billion revenue in 2024. The FDA in February said Wegovy was no longer in shortage and ended the exception that allowed sale of mass compounded copies of the patented medication. Hims and its rivals have pivoted to what they say are customized copies of Wegovy that should not be subject to the FDA decision, featuring smaller doses or allowing for a more individualized plan for increasing dosage than offered by Novo. But analysts said that personalization strategy may not be enough to stave off new legal challenges from Novo. "It remains to be seen whether HIMS method of personalization (titration and dosage) is enough to meet the compounding clinical exemption need," said Jailendra Singh, a healthcare analyst at Truist.
Yahoo
2 days ago
- Business
- Yahoo
Hims to cut 4% of workforce amid ban on weight-loss drug copies
By Amina Niasse NEW YORK (Reuters) -Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug Administration ban on compounded copies of Wegovy, made by Novo Nordisk, took effect on May 22. Hims shares have since dropped 14%. The company said it is seeking new opportunities for growth, including an agreement with Novo to help patients access Wegovy. Hims plans to enter the market for low testosterone and menopause treatments and is looking at offerings to improve longevity and sleep. "These changes are focused on sharpening how we execute, without affecting our priorities or the specialties we're committed to," a company spokesperson said regarding the layoffs. Hims still plans to hire for roles related to its long-term growth plans. Bloomberg News reported the job cuts earlier on Friday. In 2022, the FDA declared a shortage of Wegovy, which has been shown to help patients lose around 15% of their body weight. That declaration allowed compounding pharmacies to produce the drug to meet demand. The FDA in February said Wegovy was no longer in shortage and ended the exception that allowed sale of mass compounded copies of the patented medication. Hims began offering copies of Wegovy in 2024, often at far lower prices than the brand-name version. That boosted subscriptions to the Hims telehealth platform, with revenue up 111% on a yearly basis during the first quarter of 2025. Wegovy copies and similar GLP-1 weight-loss drugs accounted for $200 million of the company's $1.5 billion revenue in 2024. Hims and its rivals have pivoted to what they say are customized copies of Wegovy that should not be subject to the FDA decision, featuring smaller doses or allowing for a more individualized plan for increasing dosage than offered by Novo. But analysts said that personalization strategy may not be enough to stave off new legal challenges from Novo. "It remains to be seen whether HIMS method of personalization (titration and dosage) is enough to meet the compounding clinical exemption need," said Jailendra Singh, a healthcare analyst at Truist. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
The Cigna Group (CI): A Bull Case Theory
We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares' Substack. In this article, we will summarize the bulls' thesis on CI. The Cigna Group (CI)'s share was trading at $312.68 as of 22nd May. CI's trailing and forward P/E were 17.43 and 10.65 respectively according to Yahoo Finance. adriaticfoto/ Cigna's new deal with Eli Lilly and Novo Nordisk to offer capped prices for GLP-1 weight loss drugs may seem disruptive at first glance, particularly to players like Hims, but it reinforces the structural dynamics that benefit the company. As the fourth-largest pharmacy benefit manager (PBM) in the U.S., Cigna's concession reflects the intense competition between Lilly and Novo to scale their relatively undifferentiated GLP-1 offerings. While this specific deal may cap prices for GLP-1s, PBMs will likely offset this by inflating prices elsewhere, consistent with their broader business model that thrives on the complexity and pricing inefficiencies of the U.S. healthcare system. For Hims, which isn't fundamentally a GLP-1 business but rather a vertically integrated healthcare platform, the overall inflationary environment driven by PBMs enhances its value proposition—offering lower-cost, high-efficiency solutions below copay. Hims has guided for $750 million in 2025 weight loss revenue, largely from oral alternatives and generic liraglutide, both significantly cheaper than branded injectables like Wegovy. Hims's platform, which continues to evolve with personalized care and efficiency gains, is uniquely positioned to address a broad array of health needs in a way that is difficult for traditional PBM-centered models to replicate. The company's partnership with Novo and potential future deal with Lilly would further de-risk its growth. With a recent acquisition of a peptide manufacturing facility and a pipeline far beyond GLP-1s, Hims is building a scalable, cost-effective precision medicine platform. As the market remains fixated on GLP-1 narratives, Hims quietly compounds free cash flow and strategic value, offering investors an increasingly attractive long-term opportunity. We have previously covered The Cigna Group (CI) in January 2025 wherein we summarized a bull thesis by Tsachy Mishal on twitter. Mishal named Cigna (CI) a top pick, citing its stable model and low valuation. Since then, the company has completed a $3.7B asset sale and is on track to repurchase up to 12% of its shares. With political risk around PBMs easing and strong buyback execution, Cigna remains undervalued and well-positioned for continued upside. As of May 2025, the stock has risen by 13.23%. The Cigna Group (CI) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 72 hedge fund portfolios held CI at the end of the fourth quarter which was 66 in the previous quarter. While we acknowledge the risk and potential of CI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
The Cigna Group (CI): A Bull Case Theory
We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares' Substack. In this article, we will summarize the bulls' thesis on CI. The Cigna Group (CI)'s share was trading at $312.68 as of 22nd May. CI's trailing and forward P/E were 17.43 and 10.65 respectively according to Yahoo Finance. adriaticfoto/ Cigna's new deal with Eli Lilly and Novo Nordisk to offer capped prices for GLP-1 weight loss drugs may seem disruptive at first glance, particularly to players like Hims, but it reinforces the structural dynamics that benefit the company. As the fourth-largest pharmacy benefit manager (PBM) in the U.S., Cigna's concession reflects the intense competition between Lilly and Novo to scale their relatively undifferentiated GLP-1 offerings. While this specific deal may cap prices for GLP-1s, PBMs will likely offset this by inflating prices elsewhere, consistent with their broader business model that thrives on the complexity and pricing inefficiencies of the U.S. healthcare system. For Hims, which isn't fundamentally a GLP-1 business but rather a vertically integrated healthcare platform, the overall inflationary environment driven by PBMs enhances its value proposition—offering lower-cost, high-efficiency solutions below copay. Hims has guided for $750 million in 2025 weight loss revenue, largely from oral alternatives and generic liraglutide, both significantly cheaper than branded injectables like Wegovy. Hims's platform, which continues to evolve with personalized care and efficiency gains, is uniquely positioned to address a broad array of health needs in a way that is difficult for traditional PBM-centered models to replicate. The company's partnership with Novo and potential future deal with Lilly would further de-risk its growth. With a recent acquisition of a peptide manufacturing facility and a pipeline far beyond GLP-1s, Hims is building a scalable, cost-effective precision medicine platform. As the market remains fixated on GLP-1 narratives, Hims quietly compounds free cash flow and strategic value, offering investors an increasingly attractive long-term opportunity. We have previously covered The Cigna Group (CI) in January 2025 wherein we summarized a bull thesis by Tsachy Mishal on twitter. Mishal named Cigna (CI) a top pick, citing its stable model and low valuation. Since then, the company has completed a $3.7B asset sale and is on track to repurchase up to 12% of its shares. With political risk around PBMs easing and strong buyback execution, Cigna remains undervalued and well-positioned for continued upside. As of May 2025, the stock has risen by 13.23%. The Cigna Group (CI) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 72 hedge fund portfolios held CI at the end of the fourth quarter which was 66 in the previous quarter. While we acknowledge the risk and potential of CI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Health Line
22-05-2025
- Health
- Health Line
BlueChew vs. Hims for ED: Pricing, Treatments, and Reviews in 2025
BlueChew and Hims are both online services that offer treatments for erectile dysfunction. Read our side-by-side comparison of the types of treatments they offer, and see which is best for you. BlueChew vs. Hims comparison Since the first treatments hit the market more than 20 years ago, erectile dysfunction (ED) medications have become a multibillion-dollar industry. Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a similar business model, but what are the differences between BlueChew and Hims, and which one might be right for you? BlueChew vs. Hims: Overview Founded in 2017, Hims is a telemedicine platform that offers medical services and treatments related to sexual health, hair loss, anxiety, skin care, and more. Hims connects its customers with licensed medical professionals who can diagnose and prescribe medications during a virtual appointment, including ED medications. Then, you can receive monthly deliveries of your Hims prescriptions. BlueChew is another telemedicine platform founded in 2014 that offers online medical services and monthly subscriptions for ED medications. You'll meet with a licensed medical professional during a virtual visit and receive a prescription for an ED medication. BlueChew specializes in chewable ED medications approved by the Food and Drug Administration (FDA), such as sildenafil, tadalafil, and vardenafil. How to get started with BlueChew or Hims BlueChew Starting an order with BlueChew requires going to its website. You'll select your preferred medication and plan and fill out a medical profile there. The questions cover basic information about your age and health and more specific ones that help the doctors ensure that BlueChew's medications are safe for you to use. You'll also have to send them a picture of you holding a photo ID to verify your identity. Most medical reviews take just 1 to 2 days. After that, you'll get a supply of pills sent each month. You can also have your prescriptions filled at a compounding pharmacy near you. Get started with BlueChew Hims The ordering and consultation process for Hims is very similar to BlueChew's. The main difference is that after filling out the form on the Hims website, you can get an immediate video, phone, or online chat consultation with a doctor. Once they've determined the right medication for you, they'll write a prescription you can order from the Hims website or take to your preferred local or mail-order pharmacy. BlueChew vs. Hims: Company reputation and customer reviews BlueChew BlueChew has been in business since 2014, and its rating on the Better Business Bureau (BBB) is low. However, there are only 14 reviews on the site. Most customer complaints seem to be related to shipping and billing issues. Some reviews show that people received orders they didn't want. As of this writing, BlueChew has very few customer reviews available online besides the glowing ones on its website. Hims Hims has been available since 2017, and there are many negative reports from Hims customers who were unhappy about canceled or delayed appointments or persistent charges for medications they don't want. Positive reviews claim that Hims products were effective and that customer service was good. Overall, Hims reviews are mixed. Frequently asked questions about Hims and BlueChew What is the difference between BlueChew and Hims? If you have other conditions you want to address, like hair loss or skin concerns, you might want to try Hims because it has a much bigger product line. If you have trouble swallowing whole pills, BlueChew's chewable tablets might be best for you. BlueChew will likely also be less expensive for most ED treatment options. If you have other conditions you want to address, like hair loss or skin concerns, you might want to try Hims because it has a much bigger product line. If you have trouble swallowing whole pills, BlueChew's chewable tablets might be best for you. BlueChew will likely also be less expensive for most ED treatment options. Do you need a prescription to use BlueChew or Hims? You don't need to bring a prescription to BlueChew or Hims to buy the products. With both services, you'll have an online consultation with a doctor who will write a prescription that you can fill on the website or at a pharmacy of your choice. With BlueChew, you'll have to use a compounding pharmacy. You don't need to bring a prescription to BlueChew or Hims to buy the products. With both services, you'll have an online consultation with a doctor who will write a prescription that you can fill on the website or at a pharmacy of your choice. With BlueChew, you'll have to use a compounding pharmacy. Are BlueChew treatments approved by the FDA? BlueChew sells custom formulations of existing medications. While the active ingredients are FDA approved, the tablets you get from BlueChew are not. BlueChew sells custom formulations of existing medications. While the active ingredients are FDA approved, the tablets you get from BlueChew are not. Are Hims treatments approved by the FDA? Hims ED treatments are all FDA approved, unlike some of its products used to treat other conditions like hair loss. Hims ED treatments are all FDA approved, unlike some of its products used to treat other conditions like hair loss. Is BlueChew better than Viagra? BlueChew uses the same active ingredient as Viagra, meaning it will be likely be as effective. An older 2017 study found that chewable Viagra tablets, like BlueChew, had similar effects on the body compared to the more typical swallowable tablets. The authors wrote that chewable Viagra is a suitable alternative as people may find it easier to take. BlueChew uses the same active ingredient as Viagra, meaning it will be likely be as effective. An older 2017 study found that chewable Viagra tablets, like BlueChew, had similar effects on the body compared to the more typical swallowable tablets. The authors wrote that chewable Viagra is a suitable alternative as people may find it easier to take.
